References for: SENTENCE

Full identifier: http://www.w3.org/2000/01/rdf-schema#SENTENCE

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner.
Eva Zegelaar
2021-12-16T19:53:46.212Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner.
Eva Zegelaar
2021-12-16T19:53:44.723Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner.
Eva Zegelaar
2021-12-16T19:53:43.314Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner.
Eva Zegelaar
2021-12-16T19:53:41.879Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner.
Eva Zegelaar
2021-12-16T19:53:40.487Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner.
Eva Zegelaar
2021-12-16T19:53:38.955Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:52:03.749Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:52:01.650Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:52:00.277Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:58.726Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:57.294Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:55.872Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:54.487Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:52.362Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:50.434Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:48.690Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:46.442Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:44.771Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:43.376Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:41.806Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:40.021Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:38.360Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:36.747Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:35.273Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:33.744Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:32.317Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:30.861Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:29.242Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:27.814Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:26.377Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:24.671Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:22.639Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:21.117Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:19.586Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:18.008Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration.
Eva Zegelaar
2021-12-16T19:51:15.421Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Compared with the standard of care (SOC), Bayesian network meta-analysis (NMA) showed that dexamethasone led to lower risk of mortality with an odds ratio (OR) of 0.85 (95% CrI [0.76, 0.95]; moderate certainty) and lower risk of mechanical ventilation (MV) with an OR of 0.68 (95% CrI [0.56, 0.83]; low certainty).
Eva Zegelaar
2021-12-16T19:48:07.009Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Compared with the standard of care (SOC), Bayesian network meta-analysis (NMA) showed that dexamethasone led to lower risk of mortality with an odds ratio (OR) of 0.85 (95% CrI [0.76, 0.95]; moderate certainty) and lower risk of mechanical ventilation (MV) with an OR of 0.68 (95% CrI [0.56, 0.83]; low certainty).
Eva Zegelaar
2021-12-16T19:48:05.721Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Compared with the standard of care (SOC), Bayesian network meta-analysis (NMA) showed that dexamethasone led to lower risk of mortality with an odds ratio (OR) of 0.85 (95% CrI [0.76, 0.95]; moderate certainty) and lower risk of mechanical ventilation (MV) with an OR of 0.68 (95% CrI [0.56, 0.83]; low certainty).
Eva Zegelaar
2021-12-16T19:48:04.420Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Compared with the standard of care (SOC), Bayesian network meta-analysis (NMA) showed that dexamethasone led to lower risk of mortality with an odds ratio (OR) of 0.85 (95% CrI [0.76, 0.95]; moderate certainty) and lower risk of mechanical ventilation (MV) with an OR of 0.68 (95% CrI [0.56, 0.83]; low certainty).
Eva Zegelaar
2021-12-16T19:48:03.115Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:30.190Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:27.605Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:24.918Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:21.042Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:18.420Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:15.750Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:13.122Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:11.818Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:09.160Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:06.587Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:03.922Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:47:01.289Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:59.949Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:57.380Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:54.755Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:52.093Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:49.454Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:46.802Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:44.215Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:41.619Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:39.025Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:37.712Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:35.057Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:32.410Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:29.737Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:27.141Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:25.847Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:23.086Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:19.188Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:15.623Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:12.886Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:09.829Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:06.486Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:03.282Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:46:00.317Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:58.825Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:57.422Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:54.152Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:39.859Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:38.484Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:37.096Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:35.787Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:34.476Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
The recent announcement that RECOVERY, a randomised controlled trial comparing dexamethasone to placebo in COVID-19, was terminated early due to excess deaths in the control group further suggests patients present with secondary organising pneumonia (OP) given that corticosteroid therapy is the first-line treatment.
Eva Zegelaar
2021-12-16T19:45:33.145Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:45.105Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:43.619Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:42.329Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:41.002Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:39.450Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:37.747Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:36.138Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:34.403Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:32.681Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:31.304Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:29.723Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:28.038Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:25.649Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:23.977Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:22.299Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
SENTENCE
Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen.
Eva Zegelaar
2021-12-16T19:44:20.703Z